BRAF and neoplasm: All these analyses evidenced that even if the release of total PD1+ EVs don’t depend from intrinsic features of the patients, such as gender, LDH, NLR, PLR nor from tumor-dependent characteristics such as, number of metastatic sites, pretreatment with other therapies and BRAF status, confirming that PD1+ EVs could be consider general biomarker of innate resistance to immunotherapy with checkpoint inhibitors.